

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 August 2003 (07.08.2003)

PCT

(10) International Publication Number  
**WO 03/063608 A1**

(51) International Patent Classification<sup>7</sup>: A23J 3/16, 1/14, A23L 1/305

(21) International Application Number: PCT/EP03/00798

(22) International Filing Date: 27 January 2003 (27.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: <sup>31</sup> 29/8/04  
MI2002A000147 29 January 2002 (29.01.2002) IT

(71) Applicant (for all designated States except US): INDENA S.P.A. [IT/IT]; Viale Ortles, 12, I-20139 Milan (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DURANTI, Marcello [IT/IT]; Via Teodosio, 66, I-20131 Milano (IT). MORAZZONI, Paolo [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT).

(74) Agents: MINOJA, Fabrizio et al.; Biancheti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A PROCESS FOR THE EXTRACTION, PURIFICATION AND ENZYMATIC MODIFICATION OF SOY 7S GLOBULIN ALPHA' SUBUNIT FOR USE AS HYPOCHOLESTEROLEMIZING AGENT

(57) Abstract: A process for the extraction, purification and enzymatic modification of  $\beta$ -conglycinin  $\alpha'$  subunit, wherein  $\beta$ -conglycinin is selectively extracted from ground, deffated soy, then precipitated by treatment with aqueous ethanol; the enriched fraction is then subjected to Metal Affinity Chromatography (MAC) in denaturant conditions to obtain the  $\alpha'$  subunit, which is treated with chymotrypsin, then subjected to a further MAC to recover the amino-terminal region of this polypeptide (MW 28,000 Da).

WO 03/063608 A1

**A PROCESS FOR THE EXTRACTION, PURIFICATION AND  
ENZYMATIC MODIFICATION OF SOY 7S GLOBULIN ALPHA'  
SUBUNIT FOR USE AS HYPOCHOLESTEROLEMIZING AGENT**

The present invention relates to a process for the extraction, purification and enzymatic modification of  $\beta$ -conglycinin  $\alpha'$  subunit.

According to the invention,  $\beta$ -conglycinin is selectively extracted from ground, defatted soy, then precipitated by treatment with aqueous ethanol; the  
5 enriched fraction is then subjected to Metal Affinity Chromatography (MAC) in denaturant conditions to obtain the  $\alpha'$  subunit. The latter is treated with chymotrypsin, then subjected to a further affinity chromatography step to recover the amino-terminal region of this polypeptide (MW 28,000 Da).

**TECHNICAL BACKGROUND**

10 The known cholesterol lowering properties of soy and derivatives thereof are related with the content in isoflavones (Kirk et al., 1998) and in proteins (Anderson et. al, 1995).

Soy proteins mainly consist of glycinins (11S fraction) and  $\beta$ -conglycinins (7S fraction), the latter consisting of three subunits, named  $\alpha$ ,  $\alpha'$   
15 and  $\beta$  (Thanh and Shibasaki, 1976). Studies carried out on soy proteins have established that the 7S fraction (Lovati et. al, 1992, 1996), particularly the  $\alpha'$  subunit (Manzoni et. al, 1998) is capable of activating LDL receptor and is therefore the main responsible for the reduction of cholesterol plasma levels. In fact, treatment of an hepatic cell line with 7S globulin induces extensive  
20 degradation of the  $\alpha$  and  $\alpha'$  subunits and stimulation of LDL receptor activity, whereas  $\beta$  subunits are not degraded and the receptor is not activated. Moreover, soy mutants in which 7S fraction lacks  $\alpha'$  subunit are not able to modify the receptor activity, even at high concentrations.

As a consequence of these experimental observations, methods are

CONFIRMATION COPY

needed to obtain  $\beta$ -conglycinin in the pure form, as well as recovering and purifying the  $\alpha'$  subunit, from which specific amino acidic sequences could subsequently be obtained by enzymatic treatment, without making use of peptide synthesis.

5           The process suggested by Than et al. (1975 and 1976) and subsequently modified by O'Keefe et al. (1991) allows to separate glycinins and  $\beta$ -conglycinins based on their different solubilities at different pH; however, cross-contamination is still high and gel filtration or affinity chromatography are required, which are costly and difficult to carry out on an industrial scale.  
10       Also the modification suggested by Nagano et al. (1992), although allowing to increase the fractions purity, is still an expensive method which can be used only on laboratory scale.

          Recently, Wu et al. (1999) have described a method for separating glycinins and conglycinins on a pilot-plant scale. Glycinins are precipitated by  
15       two subsequent aqueous extractions at pH 8.5, followed by treatment of the supernatant with a 0.98 g/L bisulfite solution, while conglycinins are precipitated by adding 0.25 M NaCl to the mother liquors from the glycinins precipitation, then adjusting pH to 4.8. The process allows to treat high amounts of starting material and also provides high yields in protein, but the  
20       fractions purity is still unsatisfactory;  $\beta$ -conglycinin, in particular, undergoes degradation, apparently during diafiltration with water, which is a treatment necessary to reduce the bisulfite ions excess and to remove salts.

          The above cited methods not only do not yield pure  $\beta$ -conglycinin, but above all do not envisage separation and purification of the  $\alpha'$  subunit.

25           According to the invention, a solid fraction enriched in  $\beta$ -conglycinin is prepared by extracting a defatted ground soy in an aqueous medium according to conventional procedures and subsequently precipitating the supernatant with aqueous ethanol; the resulting fraction is then purified by Metal Affinity

Chromatography (MAC) in denaturant conditions to yield the pure  $\alpha'$  subunit, which is subjected to enzymatic treatment with chymotrypsin to obtain the amino-terminal region which has apparently the highest LDL receptor-activating activity.

## 5 DETAILED DISCLOSURE OF THE INVENTION

The present invention relates to a process for the selective extraction, purification and enzymatic modification of soy  $\beta$ -conglycinin  $\alpha'$  subunit, which process comprises the following steps:

- 10 a) extraction of a defatted ground with a sodium bisulfite aqueous solution at slightly acidic pH to obtain a  $\beta$ -conglycinin -enriched soluble protein fraction;
- b) precipitation of the  $\beta$ -conglycinin fraction from step a) by treatment with ethanol;
- c) purification of the precipitated fraction from step b) by Metal Affinity  
15 Chromatography (MAC) under denaturant conditions, to isolate the  $\alpha'$  subunit;
- d) enzymatic treatment of the  $\alpha'$  subunit from step c) with a proteolytic enzyme and further purification by MAC chromatography;
- e) precipitation of the  $\alpha'$  subunit with organic solvents.

20  $\beta$ -Conglycinin is enriched as shown in Figure 1. The starting material is soy flour, defatted by removing the lipid fraction with solvents. The material is extracted with a sodium bisulfite aqueous solution at slightly acidic pH. A solution volume ranging from 14 to 16 times the weight of the starting material, preferably from 14.5 to 15.5 times, is used. The bisulfite  
25 concentration ranges from 0.80 to 1.20 g/L, preferably from 0.90 to 1.10 g/L, most preferably from 0.95 to 1.05 g/L. The extraction is carried out for a time ranging between 14 and 18 hours at a temperature ranging from -2 to 8°C. According to a preferred embodiment of the invention, the extraction is

carried out for 16 hours with 15 volumes of a 0.98 g/L bisulfite solution at pH 6.4, at temperatures ranging from 0 to 4°C.

Under these pH and temperature conditions, glycinins solubility is very low, therefore these precipitate together with other insoluble material. The precipitate is separated by centrifugation and the soluble fraction is treated with 35 - 60% (vol/vol) aqueous ethanol, preferably 40% aqueous ethanol, at temperatures ranging from 20 to 30°C, preferably at room temperature, 25°C. The supernatant is centrifuged off and the precipitate, mainly consisting of  $\beta$ -conglycinin, is freeze-dried. The resulting powder is subjected to the subsequent step (Figure 2).

The choice to separate and purify the  $\alpha'$  subunit by means of MAC (Ostrove and Weiss, 1990) depends on its ability to coordinate metal ions such as  $Zn^{2+}$  and  $Ni^{2+}$ , as this subunit has higher histidine content than the  $\alpha$  and  $\beta$  subunits (Thanh and Shibasaki, 1978).

A matrix conjugated with zinc or nickel, preferably zinc, is used. According to a preferred embodiment of the invention, the matrix consists of iminodiacetic acid-agarose. The freeze-dried protein material is suspended in a denaturing buffer consisting of 50 mM Tris, 0.5 M NaCl, pH 7.2 and containing 5 to 8 M urea, preferably 5 M. In these conditions, the  $\alpha'$  subunit selectively binds to the matrix, and the  $\alpha$  and  $\beta$  subunits can be removed by elution with the above buffer; the  $\alpha'$  subunit is subsequently eluted with 0.1 M imidazole in the same buffer or in distilled water.

The protein fraction enriched in  $\alpha'$  subunit is collected and treated with organic solvents which precipitate the proteins, preferably with cold acetone. Acetone is used in a volume ranging from 2 to 5 times the fraction volume, preferably 3 to 4 volumes, at a temperature ranging between -10 and -30°C, preferably between -15 and -25°C. According to a preferred embodiment of the invention, 3 volumes of acetone at -20°C are used. The resulting

precipitate is separated by centrifugation, resuspended in ethanol, preferably 95% ethanol, further centrifuged and freeze-dried. The lyophilizate contains 94% of protein material and is 10 times more enriched in the  $\alpha'$  subunit than the starting material.

- 5 Table 1 shows the extraction yields in  $\beta$ -conglycinin and  $\alpha'$  subunit from soy flour.

**Table 1**

Protein fraction	Starting material	Extraction yield (% by weight)
$\beta$ -Conglycinin	Defatted flour	18.7
$\alpha'$ Subunit	$\beta$ -Conglycinin	11.0
$\alpha'$ Subunit	Defatted flour	2.1

- 10 Polypeptide fragments of the  $\alpha'$  subunit are prepared by subjecting the lyophilizate from the previous step to enzymatic treatment with a proteolytic enzyme. According to a preferred embodiment of the invention, the proteolytic enzyme is chymotrypsin and the resulting fragment mainly consists of the amino-terminal region having MW 28,000 Da.

- 15 The procedure is as follows: the lyophilizate from the previous step is dissolved at a concentration of 5 mg/ml in 0.2 M  $\text{NH}_4\text{HCO}_3$  containing 1.6 M urea at pH ranging from 7.5 to 8.5. Chymotrypsin is added in a 1:10 to 1:50 ratio, preferably 1:25 w/w to the substrate, incubating at 37°C with stirring for 24 hours. A step on MAC is subsequently carried out, as described above.

- 20 The material eluted with imidazole contains three polypeptide fragments, the main having MW 28,000 Da, and constituting the N-terminal region of the  $\alpha'$  subunit.

The administration of the  $\alpha'$  subunit and of chymotrypsin fragment to rats (table 2) proved that both are capable of remarkably decreasing cholesterol and total triglycerids plasma levels. In particular, the chymotrypsin

fragment proved not only more effective than the other soy components, but also than clofibrate, in reducing cholesterol levels, and it afforded comparable results on triglycerids.

The results of the biological experimentation suggest that the products obtainable according to the process of the present invention, in particular the  $\alpha'$  subunit and the fragments thereof, can be used as medicaments, in particular for the treatment of those pathologies which require lowering of cholesterol and/or triglycerids plasma levels. Said compounds will be used, alone or in combination with other active principles and in admixture with suitable carriers, for the preparation of pharmaceutical compositions, in particular for the treatment of hyperlipidemias. Furthermore, they can also be used for the preparation of supplements or food products for dietary regimens to be followed in the above mentioned conditions.

### EXAMPLES

#### 15 *First step: Purification of 7S globulin from soy*

The starting material was ground soy, defatted according to the Soxhlet method, using pentane as solvent.

Proteins were extracted with a 0.98 g/L NaHSO<sub>3</sub> solution in amounts 15 times the volume of the defatted ground soy, for 16 hours at temperatures ranging from 0 to 4°C, keeping pH at 6.4. After centrifugation, the supernatant was treated with 40% ethanol (vol/vol) at room temperature. The resulting precipitate, enriched in  $\beta$ -conglycinin and containing the  $\alpha'$  subunit at a double concentration than the starting material, was freeze-dried.

#### *Second step: Purification of the $\alpha'$ subunit*

25 The  $\beta$ -conglycinin enriched fraction was resuspended in denaturing buffer (50 mM Tris, 0.5 M NaCl, pH 7.2) containing 5 M urea and purified by MAC on an agarose-iminodiacetic acid matrix (Sigma) conjugated with zinc. The unbound protein material was eluted with the same buffer as above,

whereas the bound protein material, mainly consisting of the  $\alpha'$  subunit, was eluted with 0.1 M imidazole in the same buffer or in distilled water.

The  $\alpha'$  subunit- enriched fractions were treated with 3-4 volumes of acetone at  $-20^{\circ}\text{C}$ ; the resulting precipitate was suspended in 40% ethanol at room temperature, then centrifuged and freeze-dried. The resulting powder contains 94% of proteins and is 10 times more enriched in  $\alpha'$  subunit than the starting material.

### ***Third step: Enzymatic treatment of the $\alpha'$ subunit***

The lyophilizate from the above step was dissolved at a concentration of 5 mg/ml in 0.2 M  $\text{NH}_4\text{HCO}_3$  containing 1.6 M urea, at pH ranging from 7.5 to 8.5. The solution was then treated with chymotrypsin in a 1:25 w/w ratio to the protein substrate and incubated at  $37^{\circ}\text{C}$  with stirring for 24 hours, then purified by MAC as described above. The material retained by the resin and eluted with 0.1 M imidazole contains three polypeptide fragments, the major one having molecular weight 28,000 Da and consisting of the N-terminal region of the  $\alpha'$  subunit.

## **BIOLOGICAL EXPERIMENTATION**

### **Animals**

Male rats CD SPF/VAF, weighing 75-100 g, were used. The animals were housed in makrolon cages (4-5 animals per cage) in environment with automatic control of light (12 hour light/ 12 hour darkness cycles), temperature ( $21 \pm 1^{\circ}\text{C}$ ) and humidity ( $60 \pm 5\%$ ).

### **Experimental protocol**

After 7 day housing, the animals were randomly divided into seven groups of 20 rats each (Table 2). During 28 days, one group was fed with normal diet (cod. 014RF25C; Mucedola S.r.l., Settimo Milanese, MI, Italy), whereas the others were fed with hypercholesterolemic diet consisting of 1% cholesterol, 0.5% cholic acid and 25% hydrogenated coconut oil (batch



- 5      Group 1 (control): animals fed with normal diet and treated orally for 28 days with a 0.5% carboxymethylcellulose solution.
- Group 2: animals fed with hypercholesterolemic diet and treated orally for 28 days with a 0.5% carboxymethylcellulose solution.
- 10     Group 3: animals fed with hypercholesterolemic diet and treated orally for 28 days with clofibrate at a dose of 200 mg/kg.
- Group 4: animals fed with hypercholesterolemic diet and treated orally for 28 days with the soy total protein extract (TPE) at a dose of 200 mg/kg.
- 15     Group 5: animals fed with hypercholesterolemic diet and treated orally for 28 days with  $\beta$ -conglycinin at a dose of 50 mg/kg.
- Group 6: animals fed with hypercholesterolemic diet and treated orally for 28 days with the  $\alpha'$  subunit at a dose of 10 mg/kg.
- 20     Group 7: animals fed with hypercholesterolemic diet and treated orally for 28 days with the  $\alpha'$  subunit chymotrypsin fragment at a dose of 1 mg/kg.

Total cholesterol and triglycerids plasma levels were measured at the end of the 28 day treatment and after 16 hour fasting. The animals were anaesthetized with ethyl ether and blood was drawn from the inferior vena cava in tubes containing EDTA (1 mg/ml). After centrifugation for 15 min at 4°C at 3000 rpm, plasma was recovered, frozen and stored at -20°C until

measurements.

Total cholesterol and triglycerids plasma concentrations (reported in Table 2) were determined according to conventional enzymatic assays.

Table 2

5

TREATMENT	Total cholesterol (mg/dL)	Total triglycerids (mg/dL)
GROUP 1	55.4±3	105.1±7.2
GROUP 2	284.1 ± 10.3	226.9 ± 12.6
GROUP 3	191.2 ± 8.0	139.1 ± 5.8
GROUP 4	236.1 ± 10.2	176.9 ± 8.1
GROUP 5	196.4 ± 7.6	146.7 ± 5.9
GROUP 6	182.2 ± 12.1	150.1 ± 9.8
GROUP 7	175.8 ± 7.9	140.3 ± 7.4

## REFERENCES

- Anderson J.W., Bryan M.J., Cook-Newall M-E., 1995 *N. Engl. J. Med.* 333, 276-282.
- Kirk E.A., Sutherland P., Wang S.A., Chait A., LeBoeuf R.C., 1998 *Journal of Nutrition*. 128, 954-959.
- 5 Lovati M R., Manzoni C., Corsini A., Granata A., Frattini R., Fumagalli R., Sirtori C., 1992 *J. Nutr.* 122, 1971-1978.
- Lovati M.R., Manzoni C., Corsini A., Granata A., Fumagalli R., Sirtori C., 1996 *J. Nutr.* 126, 2831-2842.
- 10 Manzoni C., Lovati M.R., Gianazza E., Morita Y., Sirtori C., 1998 *J. Agric. Food. Chem.* 46, 2481-2484.
- Nagano T., Hirotaka M., Mori H., Kohyama K., Nishinari K., 1992 *J. Agric. Food Chem.* 40, 941-944.
- O'Keefe S.F., Wilson L.A., Resurreccion A.P., Murphy P.A., 1991 *J. Agric. Food. Chem.* 39, 1022-1027.
- 15 Ostrove S., Weiss S., 1990 *Methods in Enzimology* 182, 371-379.
- Thanh V.H., Okubo K., Shibasaki K., 1975 *Plant Physiol.* 56:19-22.
- Thanh V.H., Shibasaki K., 1976 *J. Agric. Food. Chem.* 24, 1117-1121.
- Thanh V.H., Shibasaki K., 1978 *J. Agric. Food Chem.* 26, 695-698.
- 20 Wu S., Murphy P.A., Johnson L.A., Fratzke A.R., Reuber M.A. 1999 *JAOCs* 76, 285-293.

**CLAIMS**


1. A process for the selective extraction, purification and enzymatic modification of soy  $\beta$ -conglycinin  $\alpha'$  subunit, which process comprises the following steps:
- 5
- a) extraction of a defatted ground soy with a sodium bisulfite aqueous solution at slightly acidic pH to obtain a  $\beta$ -conglycinin -enriched soluble protein fraction;
  - b) precipitation of the  $\beta$ -conglycinin fraction from step a) by treatment with ethanol;
  - 10 c) purification of the precipitated fraction from step b) by Metal Affinity Chromatography (MAC) under denaturant conditions, to isolate the  $\alpha'$  subunit;
  - d) enzymatic treatment of the  $\alpha'$  subunit from step c) with a proteolytic enzyme and further purification by MAC chromatography;
  - 15 e) precipitation of the  $\alpha'$  subunit with organic solvents.
2. A process as claimed in claim 1 wherein the extraction is carried out with 15 volumes of a 0.98 g/L sodium bisulfite solution at pH 6.4.
3. A process as claimed in claim 1 wherein precipitation of step b) is carried out with 40% ethanol.
- 20 4. A process as claimed in claim 1 wherein MAC in step c) is carried out on a matrix conjugated with zinc or nickel.
5. A process as claimed in claim 4 wherein the matrix is conjugated with zinc.
- 25 6. A process as claimed in claims 4 or 5 wherein the matrix consists of agarose-iminodiacetic acid.
7. A process as claimed in claim 1 wherein the denaturing agent used in MAC of step c) is urea.

8. A process as claimed in claim 1 wherein the proteolytic enzyme for the enzymatic treatment of step d) is chymotrypsin.
9. A process as claimed in claim 1 wherein precipitating solvent for the  $\alpha'$  subunit in step e) is acetone.
- 5 10. A process as claimed in claim 1 wherein the  $\beta$ -conglycinin- enriched fraction and the  $\alpha'$  subunit are stabilized by freeze-drying.
11.  $\beta$ -Conglycinin- enriched fraction and  $\alpha'$  subunit from soy obtainable with the process of claims 1-10.
12. Polypeptide fragments of soy  $\beta$ -conglycinin  $\alpha'$  subunit obtainable with  
10 the process of claims 1-10.
13. Amino-terminal polypeptide fragment obtainable according to process of claim 8.
14. Polypeptide fragments of soy  $\beta$ -conglycinin  $\alpha'$  subunit of claim 12 for use as medicament.
- 15 15. Amino-terminal polypeptide fragment of claim 12 for use as medicament.
16. The use of the polypeptide fragments of the  $\beta$ -conglycinin  $\alpha'$  subunit from soy of claim 12 for the preparation of medicaments for the treatment of hyperlipidemias.
- 20 17. The use of the polypeptide fragment of claim 12 for the preparation of medicaments for the treatment of hyperlipidemias.
18. Pharmaceutical compositions containing the polypeptide fragments of claims 12 or 13, alone or in combination with other active ingredients, in admixture with suitable carriers.
- 25 19. Supplements or alimentary products containing the polypeptide fragments of claims 12 or 13.

1/2

**Figure 1**  
 **$\beta$ -CONGLYCININ ENRICHMENT**


5



2/2

**Figure 2**  
 **$\alpha'$  SUBUNIT**

5



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/00798

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A23J3/16 A23J1/14 A23L1/305

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23J A23L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

FSTA, BIOSIS, EPO-Internal, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WU S ET AL: "Pilot-plant fractionation of soybean glycinin and beta -conglycinin." JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY , vol. 76, no. 3, 1999, pages 285-293, XP002243567 cited in the application	11
A	the whole document	1-10
A	LOVATI MARIA R ET AL: "Soy protein peptides regulate cholesterol homeostasis in Hep G2 cells." JOURNAL OF NUTRITION, vol. 130, no. 10, October 2000 (2000-10), pages 2543-2549, XP002243172 ISSN: 0022-3166 the whole document	1-19

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another claim or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*S\* document member of the same patent family

Date of the actual completion of the international search

6 June 2003

Date of mailing of the international search report

25/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

De Jong, E



## INTERNATIONAL SEARCH REPORT

 Intern: Application No  
 PCT/EP 03/00798

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LOVATI M R ET AL: "SOYBEAN PROTEIN PRODUCTS AS REGULATORS OF LIVER LOW-DENSITY LIPOPROTEIN RECEPTORS I. INDENTIFICATION OF ACTIVE BETTA-CONGLYCININ SUBUNITS" JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 46, no. 7, 1998, pages 2474-2480, XP002928070 ISSN: 0021-8561 the whole document ---	1-19
A	MANZONI C ET AL: "Soybean protein products as regulators of liver low-density lipoprotein receptors. II. alpha alpha su rich commercial soy concentrate and alpha su deficient mutant differently affect low-density lipoprotein receptor activation." JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 46, no. 7, 1998, pages 2481-2484, XP002243568 cited in the application the whole document ---	1-19
A	US 4 409 248 A (LEHNHARDT WILLIAM F ET AL) 11 October 1983 (1983-10-11) column 6, line 54 -column 8, line 41; claims 1-42 ---	1-19
A	EP 0 797 928 A (FUJI OIL CO LTD) 1 October 1997 (1997-10-01) the whole document ---	1-19
A	DATABASE WPI Section Ch, Week 199433 Derwent Publications Ltd., London, GB; Class D13, AN 1994-268692 XP002243569 & JP 06 197788 A (FUJI SEIYU KK), 19 July 1994 (1994-07-19) abstract ---	1-13
A	EP 1 172 087 A (JOHNSON & JOHNSON PACIFIC PTY) 16 January 2002 (2002-01-16) page 2, line 27-31; claims 1-8 ---	11-19
A	FR 2 784 029 A (PHARMASCIENCE LAB) 7 April 2000 (2000-04-07) page 3-4; claims 1-3 --- -/---	11-18

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

Intern:

Application No

PCT/cr 03/00798

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 77034 A (MARETTE ANDRE ; JACQUES HELENE (CA); LAVIGNE CHARLES (CA); UNIV LAV) 21 December 2000 (2000-12-21) claims 1-6 -----	14-19

## INTERNATIONAL SEARCH REPORT

Intern: Application No

PCT, L. 03/00798

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4409248	A	11-10-1983	BR 8204677 A	02-08-1983
			CA 1186549 A1	07-05-1985
			DE 3273608 D1	13-11-1986
			DK 355882 A	11-02-1983
			EP 0072617 A2	23-02-1983
			ES 8306798 A1	16-09-1983
			JP 58036347 A	03-03-1983
EP 0797928	A	01-10-1997	CN 1168770 A ,B	31-12-1997
			DE 69700759 D1	16-12-1999
			DE 69700759 T2	31-05-2000
			EP 0797928 A1	01-10-1997
			ES 2139420 T3	01-02-2000
			JP 3289770 B2	10-06-2002
			JP 9313110 A	09-12-1997
			US 6022702 A	08-02-2000
JP 6197788	A	19-07-1994	NONE	
EP 1172087	A	16-01-2002	WO 0205773 A1	24-01-2002
			AU 5432601 A	17-01-2002
			AU 7219501 A	30-01-2002
			BR 0103009 A	05-03-2002
			CA 2353057 A1	13-01-2002
			CN 1337269 A	27-02-2002
			EP 1172087 A2	16-01-2002
			JP 2002097155 A	02-04-2002
FR 2784029	A	07-04-2000	FR 2784029 A1	07-04-2000
			AU 5989499 A	26-04-2000
			CA 2346384 A1	13-04-2000
			EP 1119344 A1	01-08-2001
			WO 0019974 A1	13-04-2000
			PL 347095 A1	25-03-2002
WO 0077034	A	21-12-2000	AU 5382500 A	02-01-2001
			WO 0077034 A2	21-12-2000
			CA 2376197 A1	21-12-2000
			EP 1185289 A2	13-03-2002